Program

March 9 (Tue) 13:00-14:00 Room A

Orexin / hypocretin receptor antagonists and agonists in neuropsychiatric disorders.

Daniel Hoyer (Department of Pharmacology and Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Australia)

Mitsuhiro Yoshioka (Dept. Neuropharmacol., Hokkaido Univ. Fac. Med.)

March 9 (Tue) 11:00-12:00 Room A

Drug Discovery of Gilteritinib, novel FLT3 inhibitor, for Acute Myeloid Leukemia

Kuromitsu Sadao (Candidate Discovery Science Labs, Drug Discovery Research, Astellas Pharma Inc.)

Yasuhito Uezono (Dept. Pain Control., Jikei Univ. Sch. Med.)

March 9 (Tue) 15:30-16:30 Room A

The structural basis of class B GPCR activation and signalling

Denise Wootten (Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences)

Masamitsu Iino (Nihon Univ. Sch. Med.)

March 8 (Mon) 17:00-17:20 Room A

Studies on the novel therapeutics for Parkinson's disease-related neurodegeneration

Ichiro Kawahata (Dept. Pharmacol., Tohoku Univ.)

March 8 (Mon) 17:20-17:40 Room A

生体イメージングによる骨疾患治療薬のin vivo 薬理作用の解明

Junichi Kikuta (Dept. Immunol. & Cell Biol., Grad. Sch. Med. & Frontier Biosci., Osaka Univ.)

March 8 (Mon) 17:40-18:00 Room A

Elucidation of neuronal circuit mechanisms of learning and memory for developing new drugs for cognitive impairments

Hiroshi Nomura (Dept. Pharmacol., Grad. Sch. Pharmaceut., Hokkaido Univ.)